Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl
Autor:
Masaru Suzuki, Satoshi Oizumi, Eiki Kikuchi, Kenya Kanazawa, Hisashi Tanaka, Kaoruko Shimizu, Hiroshi Yokouchi, Ryoichi Honda, Toshiyuki Harada, Hajime Asahina, Tomoo Ikari, Kei Takamura, Tetsuya Kojima, Masao Harada, Yuka Fujita, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Takahiro Ogi, Masaharu Nishimura, Fumiko Sugaya, Satoshi Konno
Publikováno v:
Lung cancer. 138:65-71
Objectives Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospec
Publikováno v:
Lung Cancer. 133:103-109
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line standard treatment for advanced lung adenocarcinoma with mutant EGFR. Nevertheless, few studies have demonstrated the efficacy of first- and s
Autor:
Alexis B. Cortot, David Planchard, Hélène Doubre, Bénédicte Mastroianni, Sylvestre Le Moulec, Florian Guisier, Lionel Falchero, Jennifer Arrondeau, Aldo Renault, Isabelle Monnet, Laurent Greillier, Marie Wislez, L. Gérinière, Jean Bernard Auliac, Chantal Decroisette, Maurice Pérol, Eric Pichon, Catherine Daniel, Christos Chouaid, Roland Schott
Publikováno v:
Lung Cancer
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
Lung Cancer, Elsevier, 2019, 127, pp.96-102. ⟨10.1016/j.lungcan.2018.11.037⟩
International audience; Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimert
Publikováno v:
Lung Cancer. 118:105-110
Introduction The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as MET amplification. However, cohort studies of osimertinib resistance mechanism, and the correlation of MET and progression-free survival (PF
Autor:
William Pao, Matthias Freiwald, Vincent A. Miller, Scott N. Gettinger, Leora Horn, Vikram K. Chand, Egbert F. Smit, Bushi Wang, Harry J.M. Groen, D. Ross Camidge, Yelena Y. Janjigian, Jean Fan
Publikováno v:
Horn, L, Gettinger, S, Camidge, D R, Smit, E F, Janjigian, Y Y, Miller, V A, Pao, W, Freiwald, M, Fan, J, Wang, B, Chand, V K & Groen, H J M 2017, ' Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib ', Lung Cancer, vol. 113, pp. 51-58 . https://doi.org/10.1016/j.lungcan.2017.08.014
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Lung Cancer, 113, 51-58. ELSEVIER IRELAND LTD
Lung Cancer, 113, 51-58. Elsevier Ireland Ltd
Objectives In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutatio
Autor:
S. Andrew Peng, John V. Heymach, Lara Lacerda, Gustavo Schvartsman, J. Jack Lee, Marcelo F. Benveniste, Stephen G. Swisher, Emily Roarty, Frank V. Fossella, Jianjun Zhang, William N. William, Giorgios Bis
Publikováno v:
Lung Cancer. 112:90-95
Introduction Exploratory analysis of clinical trials in various tumor types have demonstrated potential improvements in overall response rate (ORR) to chemotherapy after exposure to vaccine-based immunotherapy. The objective of this retrospective stu
Autor:
Yuichiro Ohe, Masahiro Fukuoka, Yukito Ichinose, Busayamas Chewaskulyong, Nagahiro Saijo, Tony Mok, Sumitra Thongprasert, Benjamin Margono, Baohui Han, Yuri Rukazenkov, Yi-Long Wu, Helen Young, Vincent Haddad, James Chih-Hsin Yang, Patrapim Sunpaweravong, Jin-Ji Yang
Publikováno v:
Lung Cancer. 104:119-125
Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung
Autor:
Konstantin Shilo, Bo H. Chao, Bradford Siegele, Dara L. Aisner, Weiqiang Zhao, Olga B. Ioffe, David P. Carbone, Martin J. Edelman, Wilbur A. Franklin
Publikováno v:
Lung Cancer. 95:65-72
Activating mutations in the epidermal growth factor receptor (EGFR) gene are exceedingly rare in small cell lung cancer (SCLC). We present two cases of SCLC harboring EGFR mutations, one in an 82 year-old male smoker with a combined SCLC and adenocar